Repositioning Candidate Details
| Candidate ID: | R0400 |
| Source ID: | DB01645 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Genistein |
| Synonyms: | |
| Molecular Formula: | C15H10O5 |
| SMILES: | OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O |
| Structure: |
|
| DrugBank Description: | An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms. It has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode. Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417]. Natural sources of genistein include tofu, fava beans, soybeans, kudzu, and lupin. |
| CAS Number: | 446-72-0 |
| Molecular Weight: | 270.2369 |
| DrugBank Indication: | Currently Genistein is being studied in clinical trials as a treatment for prostate cancer. |
| DrugBank Pharmacology: | |
| DrugBank MoA: | Genistein may inhibit cancer cell growth by blocking enzymes required for cell growth. Genistein may decrease cardiovascular risk in postmenopausal women by interacting with the nuclear estrogen receptors to alter the transcription of cell specific genes. In randomized clinical trials, genistein was seen to increase the ratio of nitric oxide to endothelin and improved flow-mediated endothelium dependent vasodilation in healthy postmenopausal women [A14417]. In addition, genistein may have beneficial effects on glucose metabolism by inhibiting islet tyrosine kinase activity as well as insulin release dependent on glucose and sulfonylurea [A14417]. |
| Targets: | Nuclear receptor coactivator 1; Estrogen receptor alpha; Nuclear receptor coactivator 2; Steroid hormone receptor ERR2; Steroid hormone receptor ERR1; Nuclear receptor subfamily 1 group I member 2; RAC-alpha serine/threonine-protein kinase; G-protein coupled estrogen receptor 1; Cytochrome P450 1B1; Sex hormone-binding globulin; Estrogen receptor beta; DNA topoisomerase 2-alpha; Protein-tyrosine kinase 2-beta; Cystic fibrosis transmembrane conductance regulator |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|